Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPAP.L Share News (PAP)

  • There is currently no data for PAP

Broker tips: RBS, GlaxoSmithKline, Bookmakers

Thu, 20th Mar 2014 12:17
Investec has raised its rating for UK banking group Royal Bank of Scotland from 'sell' to 'hold' following the recent slump in its share price, but continues to recommend investors to avoid the stock.With the stock now trading at just 0.8 times tangible net asset value (tNAV), compared with a then-premium multiple of 1.0 in February, the broker has upgraded its rating. "However, why own RBS when profitable, defensive and dividend-rich Barclays ('buy') trades on 0.8 times [tNAV] too?" Panmure Gordon has retained a 'hold' recommendation on shares of GlaxoSmithKline after the pharmaceuticals group reported "another disappointment" for its therapeutic cancer vaccine, MAGE-A3."MAGE-A3 is a therapeutic cancer vaccine, the holy grail of the industry, but was identified as very high risk because it is an unproven area. Therefore, we believe consensus forecasts for this product are heavily risk adjusted and do not expect today's news to trigger major downgrades. Rather we view today's events as a missed upgrading opportunity."Changes to gaming machine taxes and horse racing betting levies announced in the Budget have prompted Credit Suisse to cut its forecasts and target prices for London-listed bookies Ladbrokes, William Hill and Paddy Power.The bank said that Ladbrokes, rated 'underperform', has the highest exposure to UK retail and will be most affected by these changes. It reduced its earnings estimates by 14% and 17% in 2015 and 2016, respectively, leading to a cut in the target price from 155p to 130p.BC

Related News

GSK, Hansoh's targeted cancer drug hits main survival goal in China trial
1 day ago

GSK, Hansoh's targeted cancer drug hits main survival goal in China trial

* GSK partner Hansoh reports first late-stage data ​for experimental ⁠lung cancer drug

GSK says Ris-Rez meets primary endpoint in phase 3 lung cancer trial
1 day ago

GSK says Ris-Rez meets primary endpoint in phase 3 lung cancer trial

(Alliance News) - GSK PLC on Friday announced that risvutatug rezetecan has delivered "meaningful" survival data in a "pivotal" trial for advanced or ...

GSK hails 'milestone' drug trial results in China
1 day ago

GSK hails 'milestone' drug trial results in China

(Sharecast News) - A targeted lung cancer treatment developed by GSK has shown promising results in the latest trials in China, the pharma blue chip c...

PAP.L News

Paddy Power sees 2015 operating profit up at €180m
27 Jan 2016

Paddy Power sees 2015 operating profit up at €180m

(ShareCast News) - Paddy Power said on Wednesday it expects to report a rise in full year operating profit before exceptional items as it announced a ...

Paddy Power merger with Betfair gets Irish clearance
15 Jan 2016

Paddy Power merger with Betfair gets Irish clearance

(ShareCast News) - Paddy Power's recommended merger with Betfair has received clearance from Ireland's Competition and Consumer Protection Commission....